Home » Stocks » Perrigo

Perrigo Company PLC (PRGO)

Stock Price: $53.02 USD -1.76 (-3.21%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
Pre-market: $53.03 +0.01 (0.02%) Aug 3, 7:09 AM

Stock Price Chart

Key Info

Market Cap 7.23B
Revenue (ttm) 5.00B
Net Income (ttm) 188.60M
Shares Out 136.31M
EPS (ttm) 1.37
PE Ratio 38.70
Forward PE 14.20
Dividend $0.90
Dividend Yield 1.70%

Stock Quote

Trading Day Jul 31, 2020
Last Price $53.02
Previous Close $54.78
Change ($) -1.76
Change (%) -3.21%
Day's Open 54.86
Day's Range 52.72 - 54.87
Day's Volume 1,111,218
52-Week Range 40.01 - 63.86

More Stats

Market Cap 7.23B
Enterprise Value 10.19B
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date May 28, 2020
Shares Outstanding 136.31M
Float 135.93M
EPS (basic) 1.39
EPS (diluted) 1.37
FCF / Share 2.31
Dividend $0.90
Dividend Yield 1.70%
Earnings Yield 2.58%
FCF Yield 4.35%
Payout Ratio 61.50%
Shares Short 3.89M
Short Ratio 5.04
Short % of Float 3.88%
Beta 1.21
PE Ratio 38.70
Forward PE 14.20
P/FCF Ratio 22.96
PS Ratio 1.44
PB Ratio 1.32
Revenue 5.00B
Operating Income 248.20M
Net Income 188.60M
Free Cash Flow 314.70M
Net Cash -2.96B
Net Cash / Share -21.72
Gross Margin 35.44%
Operating Margin 4.96%
Profit Margin 3.80%
FCF Margin 6.29%
ROA 2.63%
ROE 3.28%
ROIC 5.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 3
Overweight 0
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$57.57*
(8.58% upside)
Low
53.0
Current: $53.02
High
64.0
Target: 57.57
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue4,8374,7324,9465,2814,2273,9143,5403,1732,7552,268
Revenue Growth2.23%-4.34%-6.33%24.92%8%10.57%11.55%15.18%21.46%-
Gross Profit1,7731,8321,9802,0521,6441,4521,2801,096945746
Operating Income205237598-2,000673571679569490336
Net Income146131120-4,013136233442402339224
Shares Outstanding13613814214313911593.9093.2092.3091.40
Earnings Per Share1.070.950.84-28.010.972.014.684.273.632.41
EPS Growth12.63%13.1%---51.74%-57.05%9.6%17.63%50.62%-
Dividend Per Share0.820.760.640.580.460.390.350.310.270.24
Dividend Growth7.89%18.75%10.34%26.09%17.95%11.43%12.9%13.55%12.81%-
Operating Cash Flow388593699655855633554513374332
Capital Expenditures-138-103-88.60-106-137-172-104-110-99.40-57.82
Free Cash Flow250490610549718461450404275275
Cash & Equivalents354551679622786800780603310510
Total Debt3,3693,2423,3415,7975,4003,2071,9741,3698931,344
Net Cash / Debt-3,015-2,691-2,663-5,175-4,615-2,407-1,194-767-583-834
Assets11,30110,98311,62913,87019,59213,8535,3514,0243,1893,109
Liabilities5,4975,3155,4587,9138,8925,1593,0182,1711,6582,015
Book Value5,8045,6686,1715,95810,6998,6932,3331,8531,5311,094
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Perrigo Company PLC
Country Ireland
Employees 11,000
CEO Murray S. Kessler

Stock Information

Ticker Symbol PRGO
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: PRGO
IPO Date December 16, 1991

Description

Perrigo Company plc manufactures and supplies over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. It provides upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Steripod, and Rembrandt brand names. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force. Perrigo Co. plc has a partnership with NetworkWire to license Witi's patent-pending hardware and software IP in development of a smoking cessation product. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.